multifunct
compon
tumor
cell
prosurviv
machineri
biolog
function
larg
associ
proteasom
system
show
downmodul
result
reduc
cell
viabil
enhanc
peitcinduc
apoptosi
larg
extens
hela
rather
hpv
cervic
carcinoma
cell
line
moreov
demonstr
suppress
led
decreas
viral
oncoprotein
concomit
recoveri
tumor
suppressor
best
recogn
target
proteasom
degrad
express
modul
protein
level
sinc
respect
mrna
unaffect
taken
togeth
find
reveal
novel
role
host
protein
contribut
prosurviv
strategi
suggest
possibl
relev
express
level
drugradiotherapyresist
cervic
carcinoma
highrisk
human
papillomaviru
hpv
infect
major
risk
factor
larg
number
human
cancer
among
preval
cervic
cancer
hpv
subtyp
carcinogen
respons
major
cervic
cancer
case
hpvencod
oncoprotein
primari
viral
factor
respons
initi
progress
cervic
cancer
act
larg
overcom
neg
growth
regul
host
cell
protein
induc
genom
instabl
refer
therein
lower
transform
activ
abl
potenti
activ
two
viral
oncoprotein
earli
step
viral
infectiontransform
act
combin
promot
degrad
proteasom
protein
involv
cell
cycl
arrest
dna
damag
sens
repair
proapoptot
protein
well
first
best
character
protein
target
proteasom
degrad
tumor
suppressor
protein
prb
famili
turn
lead
increas
apoptosi
counteract
elev
target
proteasom
degrad
mainli
associ
cellular
ubiquitin
ligas
protein
moreov
hpv
oncoprotein
shown
upregul
sever
protein
import
cancer
develop
complex
network
interact
highrisk
hpv
viral
protein
host
protein
ultim
result
host
cell
surviv
advantag
necessari
viru
replic
cancer
develop
refer
therein
antiapoptot
cellular
machineri
includ
sever
protein
among
bag
famili
molecular
chaperon
regul
protein
member
human
bag
famili
molecular
cochaperon
protein
bag
protein
contain
evolutionarili
conserv
domain
bag
domain
bind
heat
shock
protein
cognat
protein
atpas
domain
partner
steroid
hormon
receptor
other
refer
therein
addit
contain
ww
domain
prolinerich
region
pxxp
two
conserv
ipv
ileprov
motif
mediat
bind
protein
due
presenc
sever
proteinprotein
interact
domain
structur
implic
sever
cellular
process
includ
cell
surviv
prolifer
migrat
apoptosi
gene
express
constitut
normal
cell
type
eg
skelet
muscl
heart
induc
stressor
oxid
high
temperatur
serum
depriv
normal
cell
type
prosurviv
role
signifi
overexpress
sever
human
tumor
eg
pancreat
cancer
melanoma
leukemia
appear
exert
antiapoptot
role
recent
studi
demonstr
requir
effici
growth
differ
virus
includ
varicellazost
viru
epsteinbarr
viru
herp
simplex
viru
polyomaviru
jc
sarscov
adenoviru
moreov
recent
demonstr
posit
correl
express
presenc
bovin
papilloma
viru
equin
sarcoma
best
knowledg
two
studi
report
chang
express
highrisk
hpvharbor
cell
result
contradictori
possibl
depend
experiment
model
employ
propos
candid
biomark
earli
detect
cervic
neoplasia
ranamukhaarachchi
et
al
basi
upregul
dysplast
differenti
keratinocyt
deriv
clinic
biopsi
cervic
epithelium
convers
lower
express
observ
siha
cell
harbor
compar
normal
keratinocyt
cell
line
studi
aim
investig
whether
involv
surviv
resist
proapoptot
stimuli
highrisk
cell
demonstr
downmodul
protein
sensit
hela
hpv
cell
phenethyl
isothiocyan
peitc
induc
apoptosi
impact
suppress
inactiv
machineri
hela
cell
also
explor
fetal
bovin
serum
fb
gibco
life
technolog
grand
island
ny
usa
protein
agsepharos
santa
cruz
biotechnolog
santa
cruz
ca
usa
trizol
reagent
rnase
h
ii
revers
transcriptas
random
primer
dntp
mix
purchas
invitrogen
life
technolog
sybr
green
master
mix
dnase
roch
appli
scienc
mannheim
germani
primer
custom
synthes
reagent
sigmaaldrich
st
loui
mo
usa
polyclon
antibodi
human
protein
provid
biouniversa
itali
antigapdh
mous
monoclon
mous
monoclon
rabbit
polyclon
immun
control
igg
santa
cruz
biotechnolog
clone
rabbit
monoclon
millipor
billerica
usa
mous
monoclon
abcam
cambridg
uk
peroxidaseconjug
secondari
antibodi
jackson
immunoresearch
west
grove
pa
cervic
cancer
cell
line
hela
obtain
american
type
cultur
collect
atcc
manassa
va
usa
cell
maintain
emem
dmem
biowhittak
lonza
nj
usa
media
respect
supplement
vv
fb
mm
lglutamin
antibiot
humidifi
atmospher
ensur
logarithm
growth
cell
subcultur
everi
day
specif
small
interf
rna
sirna
target
mrna
control
scrambl
scr
rna
obtain
dharmacon
thermo
fisher
scientif
lafayett
co
usa
hela
cell
cell
densiti
ml
transfect
sirna
scrrna
final
concentr
nm
use
rnaimax
reagent
invitrogen
life
technolog
cell
harvest
indic
time
point
silenc
monitor
experi
western
blot
cell
whole
lysat
immunoblot
analysi
prepar
accord
standard
protocol
protein
concentr
determin
dc
protein
assay
biorad
berkeley
ca
usa
use
bovin
serum
albumin
bsa
standard
protein
fraction
sdspage
transfer
nitrocellulos
membran
immunoblot
appropri
primari
antibodi
signal
visual
appropri
horseradish
peroxidaseconjug
secondari
antibodi
enhanc
chemiluminesc
amersham
biosciencesg
healthcar
ny
usa
densitometri
band
perform
imagej
softwar
http
rsbwebnihgov
ijdownloadhtml
detect
achiev
immunoprecipit
larg
amount
cell
lysat
mg
protein
substanti
accord
hsu
et
al
briefli
lysat
incub
antibodi
immun
control
igg
overnight
tube
rotat
thirtyf
microlit
protein
agsepharos
ad
reaction
mixtur
incub
h
immun
complex
pellet
wash
five
time
tweenpb
solut
final
centrifug
pellet
suspend
laemmli
buffer
number
viabl
cell
quantifi
mtt
tetrazolium
bromid
assay
absorpt
nm
assess
use
micropl
reader
labsystem
vienna
va
usa
experi
cell
viabil
also
check
trypan
blue
exclus
assay
use
count
chamber
cellular
dna
content
evalu
propidium
iodid
pi
stain
permeabil
cell
accord
avail
protocol
flow
cytometri
bd
facscalibur
flow
cytomet
becton
dickinson
san
jose
ca
usa
data
event
per
sampl
collect
percentag
element
hypodiploid
region
calcul
use
cellquest
softwar
phase
cell
cycl
determin
use
modfit
softwar
apoptosi
determin
human
annexin
vfitc
kit
bender
medsystem
wien
austria
accord
manufactur
instruct
green
annexin
vfitc
red
pi
fluoresc
individu
cell
measur
flow
cytometri
electron
compens
requir
exclud
overlap
two
emiss
spectra
phase
contrast
microscop
analysi
perform
use
zeiss
axiovert
microscop
zeiss
oberkochen
germani
equip
object
nm
nm
imag
acquir
randomli
select
field
scrrna
cell
harvest
h
posttransfect
centrifug
remov
dead
cell
hela
cell
cell
densiti
ml
ml
respect
ad
well
previous
coat
fibronectin
fn
allow
adher
min
well
wash
three
time
pb
remov
non
adher
cell
number
cell
determin
evalu
endogen
acid
phosphatas
pnitrophenyl
phosphat
substrat
experi
reagent
check
use
known
amount
cell
total
rna
isol
use
trizol
reagent
accord
manufactur
instruct
spectrophotometr
quantifi
rna
integr
assess
agaros
gel
electrophoresi
three
microgram
rna
revers
transcrib
qrtpcr
perform
roch
diagnost
gmbh
mannheim
germani
use
sybr
green
detect
total
volum
forward
revers
primer
mm
sybr
green
master
mix
reaction
includ
initi
cycl
min
follow
cycl
denatur
anneal
extens
rna
use
intern
standard
follow
primer
set
use
qrtpcr
assay
specif
mrna
forward
cta
caa
gct
acc
tga
revers
tct
cca
tac
aca
cag
agt
forward
tgc
tct
tag
ctg
agt
revers
cca
aga
att
tca
cct
ii
forward
ctt
cac
cgt
act
aac
revers
aag
ttc
tag
acc
cca
fold
chang
mrna
level
determin
calcul
ratio
scrrna
control
normal
signal
data
report
figur
mean
valu
sd
least
three
experi
perform
duplic
show
similar
result
differ
treatment
group
analyz
student
ttest
differ
consid
signific
p
firstli
examin
basal
express
hela
hpv
cervic
carcinoma
cell
line
blot
fig
show
express
cell
line
even
though
higher
extent
hela
cell
effici
downmodul
hela
cell
use
sirna
fig
lower
panel
report
timedepend
reduct
express
hela
cell
repres
result
obtain
cell
h
h
posttransfect
pt
level
cell
reduc
respect
compar
scrambl
rna
scrrna
transfect
cell
slight
increas
protein
scrrnaload
cell
respect
control
untransfect
cell
possibl
due
transfect
procedureinduc
stress
notabl
found
experiment
condit
downmodul
caus
reduct
cell
number
specif
hela
cell
fig
phasecontrast
microscopi
analysi
hela
cell
reveal
presenc
cell
loos
flatspindleshap
morpholog
increas
number
cell
float
medium
fig
figur
show
silenc
reduc
adhes
effici
fncoat
plate
markedli
hela
cell
thu
confirm
contribut
promot
cellmatrix
contact
specif
hela
preliminari
experi
confirm
peitc
effici
inhibit
hela
cell
growth
experiment
condit
peitc
halfmaxim
inhibitori
concentr
valu
h
two
cell
line
doserespons
curv
shown
gain
insight
mechan
underli
peitc
cell
growth
inhibit
potenti
hela
cell
titrat
effect
drug
cell
cycl
progress
apoptot
death
fig
cell
apoptosi
cell
cycl
arrest
induc
almost
simultan
hela
cell
block
seem
preced
onset
apoptosi
timecours
apoptosi
cell
cycl
arrest
induct
peitc
fig
suggest
apoptot
death
occur
subsequ
arrest
percentag
cell
accumul
increas
percentag
cell
start
grow
reduct
cell
popul
h
treatment
high
peitc
dose
panel
b
fig
concomit
increas
cell
data
shown
due
apoptot
fate
arrest
cell
rather
recoveri
cell
cycl
progress
apoptosisinduc
dna
fragment
cell
gener
inde
popul
artifactu
integr
fac
analysi
peak
pronounc
arrest
hela
compar
cell
found
correl
extens
peitcinduc
tubulin
disrupt
supplementari
fig
effect
downmodul
peitcinduc
apoptosi
hela
cell
evalu
avoid
possibl
fals
posit
result
due
silencinginduc
reduct
hela
cell
number
see
fig
adopt
follow
experiment
condit
scrrnatransfect
hela
cell
receiv
vehicl
peitc
earli
h
pt
incub
drug
h
ii
hela
cell
amount
peitc
ad
cell
lower
use
scrrnatransfect
cell
peitcinduc
apoptosi
differ
sampl
monitor
annexin
vpi
test
better
discrimin
apoptot
necrot
death
result
summar
fig
show
downmodul
allow
overcom
lowdelay
basal
hela
cell
respons
peitctrigg
prodeath
signal
result
mark
earlier
increas
cell
undergo
apoptosi
notabl
percentag
apoptot
cell
phosphatidyl
serin
expos
cell
piand
ap
pi
increas
sevenfold
hela
cell
less
twofold
cell
fig
downmodul
instead
affect
extent
involv
peitcinduc
respons
hela
cell
also
signifi
biphas
effect
drug
level
fig
agreement
stressinduc
natur
express
result
increas
peitc
dose
lower
appear
addit
immunoreact
band
slightli
higher
molecular
weight
doublet
alreadi
report
respons
other
stressinduc
chemic
notabl
increas
express
follow
mark
suppress
signal
peitc
reduct
simpli
due
gross
toxic
sinc
highli
cytotox
dose
peitc
low
effect
level
level
hela
cell
kept
low
due
proteasom
degrad
therefor
detect
signal
hela
cell
lysat
protein
load
onto
gel
figur
clearli
show
faint
signal
detect
control
scrrnatransfect
hela
cell
lysat
becam
intens
cell
qrtpcr
analysi
reveal
chang
mrna
level
thu
indic
increas
protein
level
fig
cell
intens
band
instead
unaffect
downmodul
fig
increas
signal
also
observ
hela
cell
expos
peitc
fig
left
panel
concentr
drug
caus
mark
earli
apoptot
respons
effect
reduc
per
se
protein
level
see
fig
elev
specif
hela
cell
sinc
treatment
cell
dose
peitc
led
instead
reduct
protein
fig
right
panel
next
explor
effect
reduc
express
level
viral
oncoprotein
cellular
protein
due
low
express
protein
hela
cell
sampl
enrich
protein
immunoprecipit
larg
amount
cell
lysat
detail
materi
method
use
experiment
trick
success
demonstr
presenc
immunoreact
band
appar
mw
kda
hela
cell
signal
specif
absent
cell
fig
downmodul
led
slight
highli
reproduc
decreas
immunoreact
signal
compar
control
non
transfect
scrrnatransfect
hela
cell
fig
reduc
protein
level
sinc
silenc
significantli
affect
mrna
level
fig
unlik
unaffect
downmodul
fig
stressinduc
antiapoptot
protein
overexpress
cancer
tumor
cell
line
influenc
cell
surviv
interact
differ
molecular
partner
involv
cell
develop
apoptosi
autophagi
cell
migrat
tumor
metastasi
sever
cancer
cell
model
reduct
express
lead
sensit
mani
apoptosi
induc
overexpress
reduc
sensit
apoptosi
view
demonstr
associ
biolog
function
proteasomeubiquitin
system
known
abil
high
risk
oncoprotein
target
numer
host
cell
protein
proteasom
degrad
explor
role
hela
cell
surviv
resist
druginduc
apoptosi
found
express
higher
level
hela
hpv
cervic
carcinoma
cell
line
downmodul
specif
sirna
neg
impact
hela
cell
growth
find
taken
preliminari
evid
possibl
major
prosurviv
function
cell
line
support
hypothesi
next
examin
whether
modul
might
also
differ
affect
hela
suscept
chemicalinduc
apoptosi
peitc
natur
compound
crucifer
veget
wide
investig
low
system
toxic
relev
antitumor
potenti
refer
therein
accord
previou
data
found
peitc
effici
inhibit
hela
cell
growth
promot
apoptot
death
cell
cycl
arrest
phase
howev
two
carcinoma
cell
line
display
differ
suscept
peitc
cytostat
cytotox
effect
comparison
peitc
doserespons
curv
indic
reduct
cell
number
hela
cell
due
mainli
cell
cycl
arrest
cell
apoptosi
block
moreov
kinet
arrest
apoptosi
induct
fix
peitc
dose
show
hela
cell
onset
apoptosi
delay
occur
mainli
arrest
cell
notabl
found
downmodul
sensit
hela
cell
peitctrigg
proapoptot
signal
result
mark
earli
increas
cell
undergo
apoptosi
enhanc
apoptot
respons
peitc
appear
cell
typespecif
sinc
suppress
increas
moder
respons
cell
tumor
suppressor
control
express
sever
protein
involv
apoptosi
control
cell
cycl
inhibit
transactiv
function
promot
cell
death
andor
cell
cycl
arrest
presenc
mutat
gene
perturb
function
inde
common
featur
sever
human
cancer
cervic
carcinoma
hpv
cell
express
mutat
hela
cell
express
wildtyp
howev
viral
oncoprotein
strongli
affect
statu
hpvinfect
cell
mainli
promot
proteasom
degrad
inhibit
transactiv
restor
high
risk
hpv
cell
shown
posit
correl
increas
suscept
undergo
apoptosi
respons
chemic
physic
agent
regard
peitc
literatur
data
suggest
involv
pathway
peitc
cell
growth
inhibit
cell
typespecif
demonstr
suppress
addit
enhanc
apoptot
respons
hela
cell
peitc
caus
signific
increas
result
could
taken
evid
role
restor
pathway
peitcinduc
apoptosi
hela
cell
possibl
relationship
suppress
recoveri
commit
hela
cell
toward
death
fate
also
support
even
conclus
proven
observ
treatment
hela
cell
highli
cytotox
peitc
concentr
result
decreas
concomit
increas
convers
restor
hela
cell
silenc
affect
extent
arrest
induc
peitc
lack
role
peitc
cytostat
effect
complet
surpris
view
well
establish
abil
peitc
target
tubulin
consequ
promot
disrupt
accordingli
mark
earlier
tubulin
decreas
hela
cell
well
correl
pronounc
arrest
supplementari
fig
unlik
hela
cell
cell
level
unaffect
downregul
treatment
highli
cytotox
peitc
dose
reduc
mutat
protein
result
agreement
previou
studi
wang
et
al
also
demonstr
select
deplet
mutat
protein
result
higher
basal
suscept
peitcinduc
apoptosi
cell
express
mutat
compar
cell
wildtyp
contrast
found
suppress
result
recoveri
made
hela
suscept
cell
peitc
proapoptot
signal
although
result
wang
et
al
could
gener
cell
type
exclud
mechan
addit
recoveri
wildtyp
contribut
silencinginduc
hela
cell
sensit
peitc
cytotox
effect
recoveri
hela
cell
induc
suppress
express
mediat
posttranscript
mechan
sinc
level
mrna
unaffect
proteasom
degrad
main
exclus
posttranscript
mechan
respons
low
level
hpvinfect
cell
shown
promot
proteasom
degrad
well
establish
ubiquitinationdepend
pathway
also
ubiquitinationindepend
pathway
moreov
inactiv
also
inhibit
posttransl
modif
ie
phosphoryl
acetyl
requir
transactiv
also
stabil
appropri
experiment
condit
allow
us
detect
express
low
level
hela
cell
demonstr
suppress
caus
decreas
support
silencinginduc
impair
degrad
machineri
one
mechan
respons
elev
transcript
factor
hela
cell
cellular
ubiquitin
ligas
cooper
ubiquitin
subsequ
proteasom
degrad
instead
unaffect
downmodul
intracellular
level
regul
balanc
express
proteasom
degrad
show
silenc
affect
protein
level
basi
result
consid
well
known
associ
function
proteasom
system
could
hypothes
suppress
allow
effici
proteasom
degrad
viral
oncoprotein
howev
recogn
one
partner
thu
might
contribut
stabil
assistingsustain
bind
viral
oncoprotein
partner
name
pdz
domaincontain
protein
shown
relev
stabil
present
studi
due
low
basal
level
viral
oncoprotein
consequ
tumor
suppressor
hela
cell
model
unabl
investig
depth
possibl
mechan
silenc
promot
elev
reduct
cell
studi
cell
overexpress
need
address
question
conclus
present
studi
reveal
role
sustain
disrupt
suggest
one
mechan
involv
hela
cell
sensit
peitc
higher
express
hela
compar
hpv
might
turn
result
posit
feedback
loop
sustain
infect
cell
surviv
moreov
demonstr
abil
peitc
promot
per
se
recoveri
possibl
deplet
might
provid
rational
previous
shown
peitcinduc
sensit
hela
cell
apoptosi
induc
cisplatin
chemotherapeut
method
routin
use
cervic
cancer
treatment
sinc
cisplatin
also
report
prevent
degrad
combin
treatment
cell
two
drug
could
actual
result
fast
mark
restor
hela
cell
consequ
apoptot
death
work
present
carri
collabor
author
rc
er
carri
laboratori
experi
analyz
data
interpret
result
ab
dg
perform
statist
analysi
particip
literatur
search
data
present
mab
conceiv
biochem
studi
design
coordin
experi
draft
manuscript
author
approv
final
manuscript
submit
biouniversa
srl
produc
antibodi
provid
free
charg
studi
ab
sharehold
compani
biouniversa
provid
use
antibodi
remain
author
declar
conflict
interest
